It was shown that irisin levels were lower in patients with both postmenopausal osteoporosis and sarcopenia than in healthy subjects, so scientific evidence to date shows that irisin could be used as a biomarker for these two diseases. Here, FNDC5 is linked to postmenopausal osteoporosis.